Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
222.16
-8.09 (-3.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
June 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
May 26, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
↗
May 24, 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge
↗
May 04, 2026
Via
Chartmill
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss
↗
February 23, 2026
Via
Chartmill
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch
↗
May 12, 2026
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive...
Via
MarketBeat
3 Stocks Poised to Disrupt the Healthcare Market by 2030
↗
May 08, 2026
The old healthcare model is breaking down.
Via
The Motley Fool
Topics
Artificial Intelligence
Axsome Therapeutics Recognizes Mental Health Month
May 07, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Overlooked Stocks Set to Soar in 2026
↗
May 05, 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Via
The Motley Fool
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 05, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
↗
May 04, 2026
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Via
The Motley Fool
Axsome (AXSM) Q1 2026 Earnings Call Transcript
↗
May 04, 2026
Axsome (AXSM) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome (AXSM) Q2 2025 Earnings Transcript
↗
May 04, 2026
Axsome (AXSM) Q2 2025 Earnings Transcript
Via
The Motley Fool
Axsome (AXSM) Q1 2025 Earnings Call Transcript
↗
May 04, 2026
Axsome (AXSM) Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 04, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Why Axsome Therapeutics Stock Jumped Over 20% in April
↗
May 02, 2026
Axsome shares reached an all-time high last month, and there might be more to come.
Via
The Motley Fool
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
May 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Is This Healthcare Stock a Millionaire Maker?
↗
April 08, 2026
If it can establish itself as a leading biotech in the future, it might be.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
April 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
↗
March 25, 2026
The next 10 months might be challenging for this biotech.
Via
The Motley Fool
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
↗
March 18, 2026
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Via
The Motley Fool
2 Under-the-Radar Stocks to Buy and Hold
↗
March 10, 2026
These biotechs are slowly making a name for themselves.
Via
The Motley Fool
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision
↗
March 09, 2026
This CNS drug developer with a diverse pipeline just saw a key insider trim their stake, according to recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Axsome Therapeutics to Participate in Upcoming Investor Conferences
February 25, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
February 24, 2026
NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial...
Via
MarketMinute
Topics
Economy
Initial Public Offering
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
February 24, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock
↗
February 23, 2026
TD Cowen analyst Joseph Thome’s new price target represents a potential upside of about 23% from AXSM’s current trading levels.
Via
Stocktwits
Topics
Artificial Intelligence
Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad
February 23, 2026
As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.